Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2001

View Archived Issues

Next 12 months predicted to be most productive period in BMS discovery and development history

Abbott terminates ABS-103 licensing agreement

Phytopharm's dementia treatment enters clinical testing

Phase Ib laboratory analysis complete of Helivax vaccine against H. pylori

Medarex and m-phasys collaborate on human antibody therapeutics development

Preclinical study supports use of Hemopure for acute blood loss following trauma

PRS-211095: a new neuroprotective dexanabinol analogue

Tolvaptan as an alternative to fluid restriction in hyponatremia

Primary endpoint reached in CART-1 trial of AGI-1067; data discussed in Anaheim

Phase II results of multigene DNA vaccine against malaria

Testosterone buccal tablet proves successful in phase III comparative trials

Active Biotech cleared to begin phase II trials of TTS in renal cell cancer

Development of VP-50406 discontinued for treatment of hepatitis C

Onco TCS pilot phase II trials expanded to include combination therapy with etoposide

AHA news: preliminary phase II data demonstrate significant increase in HDL cholesterol on JTT-705

Tezosentan in acute decompensated heart failure and acute coronary syndrome

Point Biomedical myocardial perfusion agent compares favorably to SPECT in phase II study

Antiarthritic agent with novel mechanism of action presented at ACR/ARHP meeting

Plenary VII: Late Breaking Clinical Trials webcast now available to DailyDrugNews.com readers

Sustained antiarthritic activity demonstrated in animal model for modified form of IL-1ra

Therapeutic potential of selective JNK inhibitor in epilepsy and stroke

General Hospital Corporation reveals novel method for treating neurodegenerative diseases

Cannabinoid antagonists claimed by Solvay for CNS, gastrointestinal and cardiovascular disorders

Ortho-McNeil synthesizes new calcium channel antagonists

Lipase inhibitors from Aventis useful for hyperlipidemia-related conditions

COX-2-inhibitory pyrazole derivatives identified at Pfizer

AtheroGenics patents VCAM-1 expression inhibitors and potential uses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...